Doubly Constrained C-terminal of Roc (COR) Domain-Derived Peptides Inhibit Leucine-Rich Repeat Kinase 2 (LRRK2) Dimerization
Missense mutations along the leucine-rich repeat kinase 2 (LRRK2) protein are a major contributor to Parkinson's Disease (PD), the second most commonly occurring neurodegenerative disorder worldwide. We recently reported the development of allosteric constrained peptide inhibitors that target and downregulate LRRK2 activity through disruption of LRRK2 dimerization. In this study, we designed doubly constrained peptides with the objective of inhibiting C-terminal of Roc (COR)-COR mediated dimerization at the LRRK2 dimer interface. We show that the doubly constrained peptides are cell-permeant, bind wild-type and pathogenic LRRK2, inhibit LRRK2 dimerization and kinase activity, and inhibit LRRK2-mediated neuronal apoptosis, and in contrast to ATP-competitive LRRK2 kinase inhibitors, they do not induce the mislocalization of LRRK2 to skein-like structures in cells. This work highlights the significance of COR-mediated dimerization in LRRK2 activity while also highlighting the use of doubly constrained peptides to stabilize discrete secondary structural folds within a peptide sequence.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
ACS chemical neuroscience - 14(2023), 11 vom: 07. Juni, Seite 1971-1980 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pathak, Pragya [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.06.2023 Date Revised 16.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1021/acschemneuro.3c00259 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357030435 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357030435 | ||
| 003 | DE-627 | ||
| 005 | 20231226071721.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acschemneuro.3c00259 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1190.xml |
| 035 | |a (DE-627)NLM357030435 | ||
| 035 | |a (NLM)37200505 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pathak, Pragya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Doubly Constrained C-terminal of Roc (COR) Domain-Derived Peptides Inhibit Leucine-Rich Repeat Kinase 2 (LRRK2) Dimerization |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.06.2023 | ||
| 500 | |a Date Revised 16.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Missense mutations along the leucine-rich repeat kinase 2 (LRRK2) protein are a major contributor to Parkinson's Disease (PD), the second most commonly occurring neurodegenerative disorder worldwide. We recently reported the development of allosteric constrained peptide inhibitors that target and downregulate LRRK2 activity through disruption of LRRK2 dimerization. In this study, we designed doubly constrained peptides with the objective of inhibiting C-terminal of Roc (COR)-COR mediated dimerization at the LRRK2 dimer interface. We show that the doubly constrained peptides are cell-permeant, bind wild-type and pathogenic LRRK2, inhibit LRRK2 dimerization and kinase activity, and inhibit LRRK2-mediated neuronal apoptosis, and in contrast to ATP-competitive LRRK2 kinase inhibitors, they do not induce the mislocalization of LRRK2 to skein-like structures in cells. This work highlights the significance of COR-mediated dimerization in LRRK2 activity while also highlighting the use of doubly constrained peptides to stabilize discrete secondary structural folds within a peptide sequence | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a LRRK2 | |
| 650 | 4 | |a Parkinson’s disease | |
| 650 | 4 | |a allosteric inhibition | |
| 650 | 4 | |a constrained peptides | |
| 650 | 4 | |a kinase | |
| 650 | 4 | |a stapled peptide | |
| 650 | 7 | |a Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Leucine |2 NLM | |
| 650 | 7 | |a GMW67QNF9C |2 NLM | |
| 650 | 7 | |a Protein Serine-Threonine Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Peptides |2 NLM | |
| 700 | 1 | |a Alexander, Krista K |e verfasserin |4 aut | |
| 700 | 1 | |a Helton, Leah G |e verfasserin |4 aut | |
| 700 | 1 | |a Kentros, Michalis |e verfasserin |4 aut | |
| 700 | 1 | |a LeClair, Timothy J |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xiaojuan |e verfasserin |4 aut | |
| 700 | 1 | |a Ho, Franz Y |e verfasserin |4 aut | |
| 700 | 1 | |a Moore, Timothy T |e verfasserin |4 aut | |
| 700 | 1 | |a Hall, Scotty |e verfasserin |4 aut | |
| 700 | 1 | |a Guaitoli, Giambattista |e verfasserin |4 aut | |
| 700 | 1 | |a Gloeckner, Christian Johannes |e verfasserin |4 aut | |
| 700 | 1 | |a Kortholt, Arjan |e verfasserin |4 aut | |
| 700 | 1 | |a Rideout, Hardy |e verfasserin |4 aut | |
| 700 | 1 | |a Kennedy, Eileen J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ACS chemical neuroscience |d 2010 |g 14(2023), 11 vom: 07. Juni, Seite 1971-1980 |w (DE-627)NLM19578832X |x 1948-7193 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g number:11 |g day:07 |g month:06 |g pages:1971-1980 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acschemneuro.3c00259 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |e 11 |b 07 |c 06 |h 1971-1980 | ||